Peer-reviewedCC BYInternational journal of molecular sciences
Advances in Treatment of Refractory Advanced and Recurrent Cervical Adenocarcinoma: Molecular Heterogeneity and Differences from Squamous Cell Carcinoma
Related
- Faecal microbiota transplantation for treatment of chronic urticaria with recurrent abdominal pain and food allergy
- Gut microbiota and treatment response heterogeneity across pharmacological therapies for MASH
- Sodium butyrate inhibits the proliferation of temozolomide-resistant glioblastoma (A172) and lung adenocarcinoma (A549) cells and biphasically regulates EGFR expression
- Spatial multi-omics uncovers an invasive-desmoplastic cellular community with prognostic and therapeutic implications in pancreatic ductal adenocarcinoma
- p38α Signaling Is Associated with Pancreatic Ductal Adenocarcinoma Progression and Represents a Potential Therapeutic Vulnerability
BibTeX
@article{anon2026advances,
title = {{Advances in Treatment of Refractory Advanced and Recurrent Cervical Adenocarcinoma: Molecular Heterogeneity and Differences from Squamous Cell Carcinoma}},
journal = {International journal of molecular sciences},
year = {2026},
month = sep,
url = {https://europepmc.org/article/PMC/PMC13664901},
note = {CC BY},
}
RIS
TY - JOUR
TI - Advances in Treatment of Refractory Advanced and Recurrent Cervical Adenocarcinoma: Molecular Heterogeneity and Differences from Squamous Cell Carcinoma
PY - 2026
DA - 2026/09/27
JO - International journal of molecular sciences
UR - https://europepmc.org/article/PMC/PMC13664901
SN - 1422-0067
ER -